ClinicalTrials.gg
RecruitingNCT04997096Updated Feb 19, 2026

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

An interventional study of Exercise and Attention Control in Ovarian Cancer, Ovarian Carcinoma and Ovarian Cancer Stage IV, sponsored by Dana-Farber Cancer Institute. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Ovarian Neoplasms by Dana-Farber Cancer Institute — 5 open to participants now, 8 under way, none of them phase 3. Ovarian Neoplasms · Dana-Farber Cancer Institute.

Planned enrollment
18th of 35
30 · median 30
Started
2022
with 2 others
No phase
13 of 36
3 open now
Registered
30th of 36
by date

Among the 36 studies in Ovarian Neoplasms by Dana-Farber Cancer Institute, this one is the 18th largest by planned enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2022, is one of 13 with no phase, and was the 30th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

5 of the 36 studies in Ovarian Neoplasms by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Ovarian Neoplasms by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).

Read the detailed description

This research study is a randomized controlled trial that will compare an exercise group to a control group on lower extremity function, CIPN, and inflammatory markers in ovarian or endometrial cancer patients undergoing first-line chemotherapy after surgery.

The names of the study interventions involved in this study are/is:

  • Aerobic and resistance exercise; virtually supervised 16-week aerobic and resistance exercise performed at home via Zoom
  • Attention control for 16 weeks, home-based stretching

The research study procedures include: screening for eligibility and study interventions including evaluations and follow up visits.

It is expected that about 30 people will take part in this research study.

03

Conditions studied

  • Ovarian Cancer
  • Ovarian Carcinoma
  • Ovarian Cancer Stage IV
  • Ovarian Cancer Stage III
  • Ovarian Cancer Stage 3
  • Endometrial Cancer
  • Endometrial Cancer Stage

Keywords

  • Ovarian Cancer
  • Ovarian Carcinoma
  • Ovarian Cancer Stage IV
  • Ovarian Cancer Stage III
  • Ovarian Cancer Stage 3
  • Endometrial Cancer
  • Aerobic Exercise
  • Strength Training
  • Cardiovascular training
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed patients with stages III-IV ovarian or endometrial cancer
  • Receiving carboplatin and paclitaxel chemotherapy after surgery
  • ≥18 years, children under the age of 18 will be excluded due to rarity of disease
  • Physician's clearance to participate in moderate-vigorous intensity exercise
  • Able to read, write, and understand English
  • Ability to understand and the willingness to sign an document
  • Willing to undergo two venous blood draws for the study

Exclusion criteria

Exclusion Criteria:

  • Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist
  • Participants with uncontrolled intercurrent illness, as determined by the treating oncologist
  • Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist
  • Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for breast cancer)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Exercise

    Participants randomized to one of two groups with 2:1 ratio: exercise (n=20) \- Aerobic and Resistance Exercise for 16 weeks

    Other: Exercise

  • Active comparator
    Attention Control

    Participants randomized to one of two groups with attention control (n=10). -Attention Control for 16 weeks home-based stretching

    Other: Attention Control

Interventions

  • OtherExercise

    16-week, virtually supervised, technology-based, aerobic and resistance exercise program performed 3 days per week which starts at least 4 weeks after surgery

  • OtherAttention Control

    Home-based stretching program consisting of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. Participants will be shown how to use the booklet and instructed on how to complete the stretching exercises by an exercise trainer.

06

What researchers measure

Primary outcomes

  1. Proportion of patients completing the exercise intervention sessions.

    The feasibility of the 16-week exercise intervention is defined as the proportion of patients completing the exercise intervention sessions. The analysis population will be the eligible patients who are assigned to the intervention group (N=20). The investigators will estimate the proportion and corresponding 95% exact confidence interval (CI).99 The Investigators expect that the proportion is 70% or higher

    Time frame: 16 Weeks

  2. Enrollment Rate

    The enrollment rate is defined as the proportion of patients who participate in the study among those patients who are approached for the enrollment.

    Time frame: 16 Weeks

Secondary outcomes

  1. Short Physical Performance Battery (SPPB)-Lower Extremity Function

    Short Physical Performance Battery (SPPB), an objective measure of lower-extremity function based on three timed tests of standing balance, walking speed, and chair stand tests, which in older adults is predictive of disability, nursing home admission, and all-cause mortality

    Time frame: 16 Weeks

  2. Change in 6-minute walk distance

    Aerobic fitness will be assessed by the 6-minute walk test (6MWT). The 6MWT has been administered in cancer survivors and has a reliability coefficient of 0.93 when tested in cancer survivors. Participants will be instructed to walk as quickly as possible without running on an indoor pre-measured walkway for 6 minutes

    Time frame: 16 weeks

  3. PROMIS- Physical function

    Physical function will be assessed using the Patient Reported Outcome Measure Information System (PROMIS) Physical Function-10 scale.

    Time frame: 16 Weeks

  4. Number of Participants with Treatment Related Adverse Events

    NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.

    Time frame: 16 Weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Feb 2029, 81 months after the start.

Of 284 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 81 months is above that.

Counting every sponsor, half of 295 studies reached it within 46 months; a quarter within 23 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2021
First posted
Aug 9, 2021
StartActual
Apr 2, 2022
Primary completionEst.
Feb 1, 2029
CompletionEst.
Apr 30, 2029
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04997096
Responsible party
Christina Dieli-Conwright, PhD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Aug 9, 2021
Start date
Apr 2, 2022
Primary completion
Feb 1, 2029 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Feb 19, 2026

Study contacts

Christina Dieli-Conwright, PhD
Contact
ChristinaM_Dieli-Conwright@dfci.harvard.edu
(617) 582-8321
Christina Dieli-Conwright, PhD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion